Выпуск
Pharmaceutical Executive Daily: FDA Approves Hibsago
Pharmaceutical Executive · 21 октября 2026 г. · 2 мин
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.